- Home
- CSTL vs GDYN Comparison
CSTL vs GDYN Comparison
Compare CSTL & GDYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- GDYN
- Stock Information
- Founded
- CSTL 2007
- GDYN 2006
- Country
- CSTL United States
- GDYN United States
- Employees
- CSTL N/A
- GDYN N/A
- Industry
- CSTL Medical Specialities
- GDYN Computer Software: Prepackaged Software
- Sector
- CSTL Health Care
- GDYN Technology
- Exchange
- CSTL Nasdaq
- GDYN Nasdaq
- Market Cap
- CSTL 697.9M
- GDYN 701.9M
- IPO Year
- CSTL 2019
- GDYN N/A
- Fundamental
- Price
- CSTL $21.62
- GDYN $7.56
- Analyst Decision
- CSTL Strong Buy
- GDYN Strong Buy
- Analyst Count
- CSTL 6
- GDYN 4
- Target Price
- CSTL $37.67
- GDYN $15.75
- AVG Volume (30 Days)
- CSTL 423.4K
- GDYN 1.2M
- Earning Date
- CSTL 11-03-2025
- GDYN 10-30-2025
- Dividend Yield
- CSTL N/A
- GDYN N/A
- EPS Growth
- CSTL N/A
- GDYN N/A
- EPS
- CSTL N/A
- GDYN 0.19
- Revenue
- CSTL $346,269,000.00
- GDYN $389,227,000.00
- Revenue This Year
- CSTL N/A
- GDYN $20.71
- Revenue Next Year
- CSTL N/A
- GDYN $11.28
- P/E Ratio
- CSTL N/A
- GDYN $39.29
- Revenue Growth
- CSTL 20.40
- GDYN 22.27
- 52 Week Low
- CSTL $14.59
- GDYN $7.37
- 52 Week High
- CSTL $35.84
- GDYN $25.50
- Technical
- Relative Strength Index (RSI)
- CSTL 50.19
- GDYN 36.57
- Support Level
- CSTL $22.54
- GDYN $7.37
- Resistance Level
- CSTL $24.74
- GDYN $8.15
- Average True Range (ATR)
- CSTL 1.14
- GDYN 0.30
- MACD
- CSTL -0.28
- GDYN 0.04
- Stochastic Oscillator
- CSTL 28.93
- GDYN 20.00
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.